Neglected Diseases

A foundation model for clinician-centered drug repurposing

Huang, K., Chandak, P., Wang, Q., Havaldar, S., Vaid, A., Leskovec, J., Nadkarni, G. N., Glicksberg, B. S., Gehlenborg, N., & Zitnik, M. (2024) · Nature Medicine · doi:10.1038/s41591-024-03233-x · Cited by 249 · see citing works

One pot synthesis of gold nanoparticles and application in chemotherapy of wild and resistant type visceral leishmaniasis

Das, S., Roy, P., Mondal, S., et al. (2013) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2013.01.061 · Cited by 135 · see citing works

Towards a sustainable system of drug development

Moors, E. H. M., Cohen, A. F., & Schellekens, H. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.03.004 · Cited by 58 · see citing works

Distributed Drug Discovery, Part 1: Linking Academia and Combinatorial Chemistry to Find Drug Leads for Developing World Diseases

Scott, W. L., & O'Donnell, M. J. (2008) · Journal of Combinatorial Chemistry · doi:10.1021/cc800183m · Cited by 46 · see citing works

The molecular analysis of Trypanosoma cruzi metallocarboxypeptidase 1 provides insight into fold and substrate specificity

Niemirowicz, G. T., Fernández, D., Solà, M., et al. (2008) · Molecular Microbiology · doi:10.1111/j.1365-2958.2008.06444.x · Cited by 28 · see citing works

Epistemic Inclusion as the Key to Benefiting from Cognitive Diversity in Science

Sikimić, V. (2023) · Social Epistemology · doi:10.1080/02691728.2023.2258831 · Cited by 22 · see citing works

Combined Approaches for Drug Design Points the Way to Novel Proline Racemase Inhibitor Candidates to Fight Chagas’ Disease

Berneman, A., Montout, L., Goyard, S., Chamond, N., Cosson, A., D’Archivio, S., Gouault, N., Uriac, P., Blondel, A., & Minoprio, P. M. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060955 · Cited by 19 · see citing works

Viability study of a multiplex diagnostic platform for Chagas disease

Foti, L., Fonseca, B. D. P. F. E., Nascimento, L. D., et al. (2009) · Memórias do Instituto Oswaldo Cruz · doi:10.1590/s0074-02762009000900019 · Cited by 17 · see citing works

In Vitro Release and In Vivo Pharmacokinetics of Praziquantel Loaded in Different Polymer Particles

Pereira, E. D., Dutra, L. D. S., Paiva, T. F., et al. (2023) · Materials · doi:10.3390/ma16093382 · Cited by 11 · see citing works

Designed mono- and di-covalent inhibitors trap modeled functional motions for Trypanosoma cruzi proline racemase in crystallography

Amaral, P. A., Autheman, D., de Melo, G. D., Gouault, N., Cupif, J., Goyard, S., Dutra, P. M. L., Coatnoan, N., Cosson, A., Monet, D., et al. (2018) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0006853 · Cited by 9 · see citing works

The evolution of TNF signaling in platyhelminths suggests the cooptation of TNF receptor in the host-parasite interplay

Bertevello, C. R., Russo, B. R. A., Tahira, A. C., et al. (2020) · Parasites & Vectors · doi:10.1186/s13071-020-04370-1 · Cited by 9 · see citing works

A global survey about undiagnosed rare diseases: perspectives, challenges, and solutions

Baldovino, S., Sciascia, S., Carta, C., Salvatore, M., Cellai, L. L., Ferrari, G., Lumaka, A. Z., Groft, S. C., Alanay, Y., Azam, M., et al. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1510818 · Cited by 8 · see citing works

The Prospects of Phytomedicines and Nanomedicines to Treat Leishmaniasis: A Comprehensive Review

Swami, R., & Aggarwal, K. (2023) · Current Drug Research Reviews · doi:10.2174/2589977515666230725105141 · Cited by 6 · see citing works

Pharmaceuticals in Society

Triggle, D. J. (2010) · Springer eBooks · doi:10.1007/978-3-642-05199-9_3 · Cited by 6 · see citing works

An explainable foundation model for drug repurposing

Bessadok, A., & Grisoni, F. (2024) · Nature Medicine · doi:10.1038/s41591-024-03333-8 · Cited by 3 · see citing works

A SOA-Based Collaborative Environment for Clinical Trials on Neglected Diseases

de Toledo, M. B. F., Nabuco, O. F., Rodrigues, M., et al. (2009) · International Conference on Advanced Information Networking and Applications Workshops (WAINA) · doi:10.1109/waina.2009.74 · Cited by 3 · see citing works

Questions éthiques soulevées par le développement des analyses de « biomarqueurs »

Ameisen, J. C. (2007) · médecine/sciences · doi:10.1051/medsci/20072310787 · Cited by 1 · see citing works

Managing University-Industry Collaborative Innovation in the Pharmaceutical Industry

Ma, Z. (2024) · doi:10.5463/thesis.499 · Cited by 1 · see citing works

Tetrazole scaffold as resourceful building blocks in chemistry and approaching their biological activities: A brief review

Agarwal, P., & Chauhan, K. (2022) · Invertis Journal of Renewable Energy · doi:10.5958/2454-7611.2022.00012.1

La Trypanosoma cruzi proline racemase, un marqueur diagnostique et de suivi pour la Maladie de Chagas ?

Coatnoan, N. (2018) · doi:10.70675/62589ea5z2107z4cddza392zff17c671dcf4

A Functional Proteomic Method for Biomarker Discovery

Reynolds, F., Panneer, N., Tutino, C. M., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022471 · Cited by 24 · see citing works

Systematic in silico discovery of novel solute carrier-like proteins from proteomesPreprint

Gyimesi, G., & Hediger, M. A. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.11.19.469292

Bio-computational identification and characterization of RNA-binding proteins in bacteria

Sharan, M. (2017)

Recent developments in analytical and functional protein microarrays.

Jona, G., & Snyder, M. (2003) · PubMed · Cited by 24 · see citing works

Systematic in silico discovery of novel solute carrier-like proteins from proteomes

Gyimesi, G., & Hediger, M. A. (2022) · PLoS ONE · doi:10.1371/journal.pone.0271062 · Cited by 34 · see citing works